Revance Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Revance Therapeutics, Inc. has filed a definitive proxy statement with the SEC.
DEF 14A: Revance Therapeutics Aims for Growth in Aesthetics and Therapeutics Markets Following FDA Approval
Revance Therapeutics outlines its strategic priorities for 2024, focusing on expanding its aesthetics portfolio and entering the therapeutics market with DAXXIFY.